Correvio Pharma (NASDAQ:CORV) announced its quarterly earnings results on Wednesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01, MarketWatch Earnings reports. Correvio Pharma had a negative net margin of 68.98% and a negative return on equity of 294.35%.
Shares of NASDAQ:CORV opened at $3.90 on Thursday. Correvio Pharma has a 52 week low of $1.46 and a 52 week high of $5.24. The firm has a market capitalization of $152.88 million, a price-to-earnings ratio of -4.33 and a beta of 0.67. The company has a debt-to-equity ratio of 4.02, a current ratio of 4.05 and a quick ratio of 3.46.
A number of equities analysts have commented on the stock. B. Riley assumed coverage on shares of Correvio Pharma in a research note on Tuesday, December 4th. They issued a “buy” rating and a $7.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $10.50 price objective on shares of Correvio Pharma in a research note on Monday, January 14th.
TRADEMARK VIOLATION WARNING: This news story was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://dakotafinancialnews.com/2019/03/14/correvio-pharma-corv-announces-earnings-results.html.
About Correvio Pharma
Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.
Featured Article: Should I invest in “strong buy” stocks?
Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.